Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
62 hedge funds and large institutions have $38.3M invested in Zynerba Pharmaceuticals, Inc in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 8 closing their positions.
68% more call options, than puts
Call options by funds: $875K | Put options by funds: $521K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
7% more funds holding
Funds holding: 58 → 62 (+4)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
33% less capital invested
Capital invested by funds: $57.1M → $38.3M (-$18.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$877K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$872K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$451K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$197K |
| 5 |
AGM
Alpine Global Management
New York
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.64M |
| 2 |
D.E. Shaw & Co
New York
|
-$920K |
| 3 |
Two Sigma Investments
New York
|
-$608K |
| 4 |
Two Sigma Advisers
New York
|
-$251K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$185K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Millennium Management
New York
| – | -$1.64M | -387,602 | Closed |
|
52
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$146K | -34,371 | Closed |
|
53
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$54K | -12,955 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$31K | -7,268 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9K | -2,170 | Closed |
|
|
CG
56
Cutler Group
San Francisco,
California
| – | -$6.29K | -1,700 | -94% |
|
|
FCM
57
Firestone Capital Management
Coral Gables,
Florida
| – | -$3K | -500 | Closed |
|
58
Bank of America
Charlotte,
North Carolina
| – | -$821 | -222 | -55% |
|
|
IF
59
Ironwood Financial
Tucson,
Arizona
| – | -$1K | -118 | Closed |
|
|
CA
60
Cornerstone Advisory
Hunt Valley,
Maryland
| – | +$92 | +25 | New |
|
|
TRCT
61
Tower Research Capital (TRC)
New York
| – | +$270 | +73 | New |
|
62
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$374 | +101 | New |
|
|
HNB
63
Huntington National Bank
Columbus,
Ohio
| – | +$803 | +217 | New |
|
ZYNE Hedge Fund Activity: Q4 2021 in Review
62 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2021, worth a combined $38.3M — down 33% from $57.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ZYNE positions and 8 closed out — a net gain of 4 holders — while 16 added to existing stakes and 18 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $877K. The largest seller was Millennium Management, exiting entirely with an estimated $1.64M sold.
- 62 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2021, up from 58 in Q3 2021.
- Funds reported $38.3M of Zynerba Pharmaceuticals, Inc stock for Q4 2021, down 33% quarter-over-quarter.
- 12 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2021 and 8 closed out, a net change of +4 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2021 was GSA Capital Partners, an estimated $877K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2021 was Millennium Management, an estimated $1.64M sold.
Based on aggregated 13F filings for Q4 2021.